In vitro and in vivo effectiveness of egg yolk antibody against Candida albicans (anti-CA IgY)

Ibrahim, Eman; Rahman, Amena; Isoda, Rie; Umeda, Kouji; Van, Nguyen; Kodama, Yoshikatsu

doi:10.1016/j.vaccine.2008.02.046

Cited by 46 publications

(29 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is due to its additional heavy-chain constant domain and carbohydrate chains. It has been demonstrated in the literature that IgY has been used in several applications, which includes quantitation of tumor biomarkers (Xiao et al, 2008) as immunotherapeutic agents against Candida albicans (Ibrahim et al, 2008), and detection of E. coli O157 (Sunwoo et al, 2006) and Salmonella (Terzolo et al, 1998;Lee et al, 2002).…”

Section: Introductionmentioning

confidence: 99%

Diagnostics of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid antigen using chicken immunoglobulin Y

et al. 2012

View full text Add to dashboard Cite

The goal of this study was to develop a quantitative detection system for severe acute respiratory syndrome-associated coronavirus (SARS-CoV), targeting the nucleocapsid protein (NP), to determine the presence and degree of infection in suspected individuals. Because the NP is the viral protein shed during infection and its template mRNA is the most abundant subgenomic RNA, it is a suitable candidate for developing antibodies for diagnostic applications. In this study, we have prepared full-length SARS-CoV NP expressed in Escherichia coli and purified. Full-length NP was used for the preparation of mouse monoclonal antibody and chicken polyclonal IgY antibodies for the development of heterosandwich ELISA for early diagnostics of SARS-suspected individuals. The sensitivity of the developed heterosandwich ELISA can detect the viral antigen at 18.5 pg/mL of recombinant NP. This study describes ultrasensitive ELISA using 19B6 monoclonal antibody as the capture antibody and IgY as the detecting antibody against the most abundant SARS-CoV NP antigens. One of the most important findings was the use of inexpensive polyclonal IgY antibody to increase the sensitivity of the detection system for SARS-CoV at the picogram level. Furthermore, the immunoassay of SARS-CoV NP antigen developed could be an effective and sensitive method of diagnosing SARS-suspected individuals during a future SARS-CoV outbreak.

show abstract

Section: Introductionmentioning

confidence: 99%

Diagnostics of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid antigen using chicken immunoglobulin Y

et al. 2012

View full text Add to dashboard Cite

show abstract

“…expressing the variable domain of llama heavy-chain antibody fragments have been proposed as a treatment for rotavirus-induced diarrhea, although currently no clinical data on safety or efficacy is available (Pant et al, 2006). Studies have also attempted to target problematic fungal and parasitic infections using antibodies (Casadevall & Pirofski, 2012;Crabb, 1998;Ibrahim et al, 2008;Nord et al, 1990;Okhuysen et al, 1998).…”

Section: Peroral Use Of Antibodiesmentioning

confidence: 99%

“…This approach would utilize oral polyclonal or monoclonal anti-TNF alpha neutralizing antibodies (or antibody secreting bacteria) to target the elevated intestinal TNF alpha concentrations seen in the active phase of these diseases (Atreya et al, 2014;Braegger et al, 1992;Tjellstrom et al, 1997;Vandenbroucke et al, 2010;Worledge et al, 2000). Oral administration of anti-TNF alpha antibodies should avoid some of the undesirable long-term side effects and opportunistic infections, including tuberculosis and non-Hodgkins lymphoma, which are caused by the generalized (Casadevall & Pirofski, 2012;Ibrahim et al, 2008) …”

Section: Peroral Use Of Antibodiesmentioning

confidence: 99%

Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications

Jones

Martino

2015

Critical Reviews in Biotechnology

View full text Add to dashboard Cite

Therapeutic antibodies provide important tools in the "medicine chest" of today's clinician for the treatment of a range of disorders. Typically monoclonal or polyclonal antibodies are administered in large doses, either directly or indirectly into the circulation, via a systemic route which is well suited for disseminated ailments. Diseases confined within a specific localized tissue, however, may be treated more effectively and at reduced cost by a delivery system which targets directly the affected area. To explore the advantages of the local administration of antibodies, we reviewed current alternative, non-systemic delivery approaches which are in clinical use, being trialed or developed. These less conventional approaches comprise: (a) local injections, (b) topical and (c) peroral administration routes. Local delivery includes intra-ocular injections into the vitreal humor (i.e. Ranibizumab for age-related macular degeneration), subconjunctival injections (e.g. Bevacizumab for corneal neovascularization), intra-articular joint injections (i.e. anti-TNF alpha antibody for persistent inflammatory monoarthritis) and intratumoral or peritumoral injections (e.g. Ipilimumab for cancer). A range of other strategies, such as the local use of antibacterial antibodies, are also presented. Local injections of antibodies utilize doses which range from 1/10th to 1/100th of the required systemic dose therefore reducing both side-effects and treatment costs. In addition, any therapeutic antibody escaping from the local site of disease into the systemic circulation is immediately diluted within the large blood volume, further lowering the potential for unwanted effects. Needle-free topical application routes become an option when the condition is restricted locally to an external surface. The topical route may potentially be utilized in the form of eye drops for infections or corneal neovascularization or be applied to diseased skin for psoriasis, dermatitis, pyoderma gangrenosum, antibiotic resistant bacterial infections or ulcerated wounds. Diseases confined to the gastrointestinal tract can be targeted directly by applying antibody via the injection-free peroral route. The gastrointestinal tract is unusual in that its natural immuno-tolerant nature ensures the long-term safety of repeatedly ingesting heterologous antiserum or antibody materials. Without the stringent regulatory, purity and clean room requirements of manufacturing parenteral (injectable) antibodies, production costs are minimal, with the potential for more direct low-cost targeting of gastrointestinal diseases, especially with those caused by problematic antibiotic resistant or toxigenic bacteria (e.g. Clostridium difficile, Helicobacter pylori), viruses (e.g. rotavirus, norovirus) or inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease). Use of the oral route has previously been hindered by excessive antibody digestion within the gastrointestinal tract; however, this limitation may be overcome by intelligently applying one or more strate...

show abstract

“…In recent studies, chicken egg yolk has been recognized as an alternative antibody source. Immunization with egg yolk immunoglobulin (IgY) has shown diagnostic and therapeutic value against fungi, bacteria and virus causing various diseases 14,15,16,17. For example, passive immunization with egg yolk IgY through intramuscular injection, oral administration, and immersion was shown to have therapeutic value in the treatment of infectious disease evoked by rotavirus, parvovirus, E. coli , S. typhimurium , S. mutans , H. pylori , and Candida albicans 16…”

Section: Introductionmentioning

confidence: 99%

Production of Egg Yolk Antibodies Specific to House Dust Mite Proteins

Lee

Han

et al. 2014

Yonsei Med J

View full text Add to dashboard Cite

PurposeHouse dust mites (HDMs) are an important source of indoor allergens associated with asthma, rhinitis and atopic dermatitis. Chicken immunoglobulin (Ig) Y is known to be a good alternative to mice and rabbit antibody production. In this study, we produced IgYs specific to HDMs and investigated their IgE immunoreactivities.Materials and MethodsTotal IgYs were isolated from the yolks of White Leghorn hens immunized with either Dermatophagoides pteronyssinus or D. farinae protein extract. Control antibodies were separated from the yolks of immunized hens with phosphate buffered saline. IgYs specific to HDMs were analyzed using enzyme-linked immunosorbent assay and Western blotting analysis.ResultsThe concentration of egg IgY specific to D. farinae in an immunized hen increased and the highest achieved was 661.3 ug/mg (per an egg) on day 47, compared with 760 ug/mg IgY specific to D. pteronyssinus on day 16. The D. pteronyssinus or D. farinae-specific IgY was detected by binding of each mite proteins, and their immunoreactivities were elevated dependent of the specific IgY concentration.ConclusionIgY specific to HDMs may be a promising antibody for immunological diagnosis as well as identification of possible resistance relating to HDM allergy.

show abstract

In vitro and in vivo effectiveness of egg yolk antibody against Candida albicans (anti-CA IgY)

Cited by 46 publications

References 40 publications

Diagnostics of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid antigen using chicken immunoglobulin Y

Diagnostics of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid antigen using chicken immunoglobulin Y

Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications

Production of Egg Yolk Antibodies Specific to House Dust Mite Proteins

Contact Info

Product

Resources

About